Transplantation in adult ALL

Area of Science:

• Hematology
• Oncology
• Transplantation Immunology

Background:

• The graft-versus-leukemia (GvL) effect is a well-established benefit in adult acute lymphoblastic leukemia (ALL).
• Optimal treatment strategies for ALL in adults require careful consideration of age and specific genetic markers.
• Allogeneic transplantation offers a potential cure but carries significant treatment-related mortality.

Purpose of the Study:

• To review the current role and evolving indications of allogeneic transplantation in adult ALL.
• To discuss age-specific considerations and risk stratification for allogeneic stem cell transplantation in ALL.
• To highlight the potential of reduced-intensity conditioning and alternative donor sources.

Main Methods:

• Review of existing literature on allogeneic transplantation outcomes in adult ALL.
• Analysis of patient subgroups based on age, cytogenetics, and disease status.
• Evaluation of treatment-related mortality and efficacy of different transplant approaches.

Main Results:

• Allogeneic transplantation is a valuable therapeutic option for adult ALL, particularly in specific patient subsets.
• Younger adults may benefit more from intensive pediatric protocols, while older adults may be candidates for reduced-intensity conditioning.
• Matched unrelated donors show comparable safety and efficacy to sibling donors in adults aged 25-45.
• Patients with Philadelphia chromosome, t(4;11), or complex karyotypes remain candidates, with salvage transplantation being a key option.

Conclusions:

• Allogeneic transplantation is a cornerstone for specific adult ALL populations, especially for salvage therapy.
• Tailoring transplant strategies based on age, risk factors, and donor availability is essential for optimizing outcomes.
• Further research into minimal residual disease monitoring and the adaptation of pediatric protocols in adults is warranted.